Harrow, Inc. (NASDAQ: HROW), a U.S.-based provider of ophthalmic disease management solutions, announced on Friday that it ...
Harrow entered into an agreement to acquire Melt Pharmaceuticals and plans to submit a new drug application for MELT-300, ...
Washingtonian on MSN
Smiles of Chevy Chase Has All Your Dental Needs With a Team You Can Trust
Under the expert guidance of Dr. Despina M. Markogiannakis, Smiles of Chevy Chase is redefining the standard of dental care ...
AMSTERDAM — Many urologic procedures can be safely performed with the use of conscious sedation rather than general anesthesia, and both clinicians and their patients say they prefer the lighter touch ...
Ethicon Endo-Surgery, a Johnson & Johnson company, announced that the SEDASYS System, the first computer-assisted personalized sedation system, was granted a CE Mark for the European Union for routine ...
New data show how Sympazan is being used in daily clinical practice to treat patients with Lennox-Gastaut Syndrome (LGS), a severe form of ...
Top5 on MSN
Top 5 Tips for Nervous Dental Patients
Do you need some tips for that dental visit. Despite the generous dose of laughing gas your dentist may administer during ...
To a certain type of person, the appeal of these procedures is self-evident: Getting a needle jabbed into your skin hurts.
Harrow plans to submit a New Drug Application (“NDA”) to the FDA in 2027, with a potential U.S. commercial launch in 2028.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback